阿立哌唑辅助氟伏沙明治疗强迫障碍的临床观察

目的：探讨阿立哌唑辅助氟伏沙明治疗强迫障碍的临床疗效及安全性。方法：将54例强迫障碍患者随机分为两组（各27例）：阿立哌唑（2．5—10mg／d）辅助氟伏沙明（250—300mg/d）组（研究组）、氟伏沙明（250～300mg／d）组（对照组），治疗观察期均为8周。两组患者于基线及治疗2、4、6、8周末分别评定Yale—Brown强迫量表（Y—BOCS），并采用副反应量表（TESS）评定治疗期间的不良反应。结果：研究组、对照组分别脱落1例、2例。研究组的强迫思维和强迫行为评分在基线及2、4、6、8周末时点间比较差异均有统计学意义（P〈0．05）；2周末时，两组间的强迫思维评分比较差异有统计学意义（P〈0．05），而强迫行为评分比较差异无统计学意义（P〉0．05）；4周末时，两组间的强迫行为评分比较差异有统计学意义（P〈0．05）；8周末时，两组间强迫症状有效率比较差异有统计学意义（P〈0．05），而不良反应发生率比较差异均无统计学意义（P〉0．05）。结论：阿立哌唑辅助氟伏沙明可有效、持续地改善强迫障碍患者的强迫症状，且不良反应发生率与单一氟伏沙明治疗相当。

Clinical Observation on Fluvoxamine and Aripiprazole as Adjunctive Therapy in the Treatment of Obsessive-compulsive Disorders

Objective： To explore the efficacy and safety of fluvoxamine and aripiprazole as adjunctive therapy in the treatment of obsessive-compulsive disorders patients.Method： Total 54 obsesslve-compulsive disorders patients were randomly divided into two groups： Fluvoxamine （ 250-300 mg/d ） auxillariad by arlpiprazole （ 2.5-10 mg/d ） group （ study group ） and fluvoxamine （ 250-300 mg/d ） group （ contral group ）, 27 for each. Each group had a 8-week treatment.The efficacy were assessed and analyzed by Yale-Brown Obsessive Compulsive Scale （ Y-BOCS ） at baseline and at week 2, 4, 6 and 8. The side effects were assessed by Treatment Emergent Syptom Scale （ TESS ） during the treatment. Result： Study group and contral group had 1, 2 case being off respectively. The obsession and compulsion scores of study group had all statistical difference at baseline and week 2, 4 , 6, 8 each other （ P〈0.05 ） . At week 2, in both groups, the obsession scores had statistical difference （ P〈0.05 ）, while the compulsion scores had no statistical difference （ P〉0.05 ） . At week 4, in both groups, the compulsion scores had statistical difference （ P〈0.05 ） . At week 8, the efficient of compulsive symptoms scores of two groups had statistical difference （ P〈0.05 ）, while the rates of side effects had all no statistical difference （ P〉0.05 ） . Conclusion： Fluvoxamine and aripiprazole as adjunctive therapy can effectively continue to improve the compulsive symptoms in the treatment of obsessive-compulsive disorders patients, the rate of side effects is similar to that of simple fluvoxamine therapy.